DNPUF (Sumitomo Pharma Co) E10: $0.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNPUF Sumitomo Pharma Co Ltd DNPUF
65 GF Score
Price $8.41
GF Value $5.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co E10?

Sumitomo Pharma Co DNPUF 65 E10 is $0.07 as of Mar. 2026. GuruFocus rates DNPUF with a GF Score™ of 65/100 and a GF Value™ of $5.49 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.013. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.07 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -47.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sumitomo Pharma Co was 12.80% per year. The lowest was -47.00% per year. And the median was 6.90% per year.

As of today (2026-07-30), Sumitomo Pharma Co's current stock price is $8.405. Sumitomo Pharma Co's E10 for the quarter that ended in Mar. 2026 was $0.07. Sumitomo Pharma Co's Shiller PE Ratio of today is 120.07.

During the past 13 years, the highest Shiller PE Ratio of Sumitomo Pharma Co was 251.47. The lowest was 7.49. And the median was 24.74.


Sumitomo Pharma Co  (OTCPK:DNPUF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sumitomo Pharma Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=8.405/0.07
=120.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Sumitomo Pharma Co was 251.47. The lowest was 7.49. And the median was 24.74.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sumitomo Pharma Co E10 Related Terms


Sumitomo Pharma Co E10 Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co E10 Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.58 -0.06 -0.06 0.07

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.05 0.08 0.07 0.07

DNPUF vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Shiller PE Ratio falls into.


DNPUF
65GF Score
Sumitomo Pharma Co Ltd DNPUF
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sumitomo Pharma Co's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.013/112.7000*112.7000
=-0.013

Current CPI (Mar. 2026) = 112.7000.

Sumitomo Pharma Co Quarterly Data

per share eps CPI Adj_EPS
201606 0.200 98.100 0.230
201609 0.063 98.000 0.072
201612 0.405 98.400 0.464
201703 0.039 98.100 0.045
201706 0.559 98.500 0.640
201709 0.471 98.800 0.537
201712 -0.032 99.400 -0.036
201803 0.227 99.200 0.258
201806 0.349 99.200 0.396
201809 0.283 99.900 0.319
201812 0.271 99.700 0.306
201903 0.196 99.700 0.222
201906 0.156 99.800 0.176
201909 0.553 100.100 0.623
201912 0.315 100.500 0.353
202003 -0.075 100.300 -0.084
202006 0.427 99.900 0.482
202009 0.454 99.900 0.512
202012 0.799 99.300 0.907
202103 -0.325 99.900 -0.367
202106 0.110 99.500 0.125
202109 0.723 100.100 0.814
202112 0.219 100.100 0.247
202203 0.213 101.100 0.237
202206 0.584 101.800 0.647
202209 -0.674 103.100 -0.737
202212 -0.209 104.100 -0.226
202303 -1.055 104.400 -1.139
202306 -0.692 105.200 -0.741
202309 -0.492 106.200 -0.522
202312 -0.874 106.800 -0.922
202403 -3.314 107.200 -3.484
202406 0.254 108.200 0.265
202409 -0.848 108.900 -0.878
202412 0.875 110.700 0.891
202503 0.041 111.100 0.042
202506 0.195 111.700 0.197
202509 1.492 112.000 1.501
202512 0.142 113.000 0.142
202603 -0.013 112.700 -0.013

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.07 mean?
Sumitomo Pharma Co (DNPUF) has a E10 of $0.07 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's E10 too high?
Sumitomo Pharma Co's current E10 is $0.07. Overall, Sumitomo Pharma Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's E10 compare to ZTS?
Sumitomo Pharma Co's E10 of $0.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current E10 is $0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.49, compared to a current price of $8.41 — trading 53.1% above its estimated fair value. The current E10 is $0.07. Sumitomo Pharma Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current E10 is $0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of $8.41 is trading 53.1% above its estimated GF Value™ of $5.49. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for DNPUF:

  • E10: $0.07
  • GF Value™: $5.49 vs. price of $8.41 (53.1% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score

Get the complete analysis for DNPUF

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.41
Price
$5.49
GF Value